Tag: CCS
DMEs improve adherence, lower costs & reduce utilization, study finds
March 25, 2025HME News Staff
DALLAS – There are significant advantages for patients receiving continuous glucose monitors through DME providers compared to pharmacies, including higher adherence rates, according to a new study published in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association.
The study, supported by CCS, demonstrates that efforts to expand access to CGMs by adding pharmacy as a new channel for distribution — alongside the established DME provider channel —...
DME providers can help physicians manage diabetes population, study finds
March 21, 2025Theresa Flaherty, Managing Editor
DALLAS – The No. 1 reason physicians cite for not prescribing a continuous glucose monitor is its complexity, a roadblock that DME providers can help clear, according to a new study from CCS.
That complexity, along with a surge in the number of diabetes patients, leaves primary care physicians and endocrinologists feeling overwhelmed and not able to keep up-to-date on technology, and, ultimately, struggling to offer enough health coaching and education to their patients. That creates...
In brief: Owens & Minor explores P&HS sale, Grassley challenges UHC, CCS details burnout
February 28, 2025HME News Staff
RICHMOND, Va.– Owens & Minor is looking to sell off its Products & Healthcare Services business, while it remains “bullish” on its Patient Direct business.
The company made the announcement today, as part of its fourth quarter and full-year 2024 earnings results.
“Our commitment to directing capital toward the higher growth and higher margin Patient Direct segment has been increasingly evident in recent years and is consistent with our strategy,” said...
CCS study: Physicians ‘overwhelmed’ by soaring diabetes numbers
February 26, 2025HME News Staff
DALLAS – The vast majority of physicians caring for people with diabetes say they are overwhelmed, according to a new study from CCS, a provider of clinical solutions and home medical supplies for those living with chronic conditions.
Eighty-five percent of endocrinologists and 58% of PCPs feel overwhelmed by the number of patients with diabetes, demonstrating that many are not in a position to properly support the ongoing education and coaching needs of people living with diabetes,...
Stakeholders push two-channel option for CGMs
November 27, 2024Theresa Flaherty, Managing Editor
WASHINGTON – Users of continuous glucose monitors have reported difficulties obtaining equipment and supplies when their insurers eliminate coverage under DME, adding more evidence that there needs to be a two-channel option, stakeholders say.
As CMS has expanded coverage of CGMs and supplies, some payers have begun making it a pharmacy-only benefit, limiting brand choices and narrowing networks.
“One patient wrote that they attempted to obtain sensors from three different...
CCS: ‘There’s something about that DME interaction’
September 27, 2024Theresa Flaherty, Managing Editor
DALLAS – People with diabetes fall off their therapy all the time for a variety of reasons, but DME providers are best equipped to catch them when they do, according to the results of a new study conducted by CCS.
DME patients reinitiated their use of continuous glucose monitors 22% of the time compared to 10% of pharmacy patients, the study found.
“I didn’t expect the difference to be that big,” said Dr. Arti Masturzo, chief medical officer at CCS. “People...
In brief: CGM outcomes, Vent360+ launch, O&P WOY, AdaptHealth refi
September 18, 2024HME News Staff
DALLAS – Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy benefit, according to peer-reviewed research conducted by CCS and published in the Journal of Medical Internet Research Diabetes (JMID).
Non-adherent patients who use CGMs also had a higher rate of therapy reinitiation when therapy was provided through a medical (22%) vs. pharmacy...
Study: Using medical benefit can result in positive outcomes
September 17, 2024HME News Staff
DALLAS – Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy benefit, according to peer-reviewed research conducted by CCS and published in the Journal of Medical Internet Research Diabetes (JMIR Diabetes).
Non-adherent patients who use CGMs also had a higher rate of therapy reinitiation when therapy was provided through a medical (22%) vs....
CCS sees AI tool as next step in diabetes care evolution
June 21, 2024Theresa Flaherty, Managing Editor
DALLAS – The volume of data being collected from diabetes patients presents an opportunity to use artificial intelligence to better understand which patients are at risk for non-adherence to therapy, says Richard Mackey, chief technology officer at CCS, which recently launched PropheSee, an AI-powered predictive model for CGM users.
“We want to deliver insights that help them anticipate whatever needs they might have (and identify) situations where some additional support or...
In brief: CCS launches PropheSee, Vertess’ Smith recognized
June 12, 2024HME News Staff
DALLAS – CCS has launched PropheSee, an AI-powered predictive model for health care organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.
With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk...